A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Descripción general
Resumen del artículo
The study proposes replacing "NAFLD" with "MASLD" (metabolic dysfunction-associated steatotic liver disease), reflecting the central role of metabolic dysfunction. It also proposes diagnostic criteria based on the presence of at least one cardiometabolic risk factor and creates a separate category ("MetALD") for patients with MASLD and increased alcohol consumption.
Explícamelo como si tuviera cinco años
Scientists changed the name of "fatty liver disease" to better show it's mostly caused by how your body uses food, not just fat. They also made a special name for people who have it and drink alcohol.
Posibles conflictos de intereses
Many authors disclosed consulting relationships with or receiving grants from pharmaceutical companies involved in NAFLD research and treatment.
Limitaciones identificadas
Explicación de la calificación
This study used a robust, multi-stage Delphi process with a diverse panel of experts and patient advocates to reach consensus on new nomenclature for fatty liver disease. The thorough methodology, global representation, and inclusion of patient perspectives are strengths. However, potential bias in the Delphi method and the declared COIs of some authors slightly lower the rating.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →